Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

(2013) Julia L. Glade Bender et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy

(2012) A. Santoro et al.   ANNALS OF ONCOLOGY

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

(2012) B. C. Widemann et al.   CLINICAL CANCER RESEARCH

Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

(2011) Margaret von Mehren et al.   CANCER

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

(2011) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma

(2011) Irene Schmid et al.   PEDIATRIC BLOOD & CANCER

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2010) C. Pena et al.   CLINICAL CANCER RESEARCH

A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

(2010) Elizabeth Fox et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

(2010) Stephen T. Keir et al.   PEDIATRIC BLOOD & CANCER

Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling

(2010) Wessen Maruwge   OncoTargets and Therapy

Management of hypertension in angiogenesis inhibitor-treated patients

(2009) H. Izzedine et al.   ANNALS OF ONCOLOGY

Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy

(2009) N. S. Azad et al.   CLINICAL CANCER RESEARCH

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

(2009) Robert G. Maki et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

(2009) Richard T. Kloos et al.   JOURNAL OF CLINICAL ONCOLOGY

The Successful Use of Sorafenib to Treat Pediatric Papillary Thyroid Carcinoma

(2009) Steven G. Waguespack et al.   THYROID

Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement

(2008) Y. C. Henderson et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasma

(2007) Lokesh Jain et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

(2007) John M. Maris et al.   PEDIATRIC BLOOD & CANCER